Characteristic | Value |
---|---|
Age [yr] | |
Median (min.–max.) | 71 (59–77) |
PSA [ng/mL] | |
Median (min.–max.) | 0.70 (0.10–10.2) |
PSA doubling time category, % (n) | |
<3 mo. | 33% (5) |
3–6 mo. | 33% (5) |
7–12 mo. | 13% (2) |
>12 mo. | 20% (3) |
Gleason Score category, % (n) | |
6 | 7% (1) |
7a | 13% (2) |
7b | 20% (3) |
8 | 27% (4) |
9 | 33% (5) |
Primary treatment, % (n) | |
Prostatectomy alone | 40% (6) |
Prostatectomy + lymphadenectomy | 47% (7) |
Radiation therapy | 13% (2) |
Additional treatments before study imaging, % (n) | |
Radiation therapy | 20% (3) |
ADT | 20% (3) |
Number of indeterminate lesions on [68Ga]Ga-PSMA-11 PET/CT | |
Total | 20 |
Median (min.–max.) per patient | 1 (1–3) |
Percentage (number) of patients with multiple indeterminate lesions | 27% (4) |
Sites(s) of indeterminate lesions on [68Ga]Ga-PSMA-11 PET/CT, % (n) | |
Local | 20% (4) |
Lymph node | 40% (8) |
Bone | 40% (8) |